Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.
Adding an oral proteasome inhibitor to chemotherapy shows promise in children with relapsed leukemia, a population desperately needing new approaches.
The TACL consortium evaluated oral ixazomib added to chemotherapy in children with relapsed ALL, addressing the urgent need for new agents in a high-mortality pediatric population. The multicenter design across children's hospitals provides robust feasibility and preliminary efficacy data for this oral proteasome inhibitor combination strategy.
What the study was
- Study design
- Multicenter prospective consortium trial
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Blood Neoplasia
Why it surfaced
TACL consortium multicenter pediatric trial; R/R childhood ALL has very high unmet need; oral proteasome inhibitor approach is novel in this histology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.